<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16611">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02890641</url>
  </required_header>
  <id_info>
    <org_study_id>GDR_2015_15</org_study_id>
    <nct_id>NCT02890641</nct_id>
  </id_info>
  <brief_title>Genetic and Electrophysiologic Study in Focal Drug-resistant Epilepsies</brief_title>
  <acronym>GENEPHY</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <brief_summary>
    <textblock>
      Genetic abnormalities in focal epilepsies are well known. A novel gene (DEPDC5) was
      identified, associated with various genotypes of epilepsies. Recently, DEPDC5 mutations were
      identified also inside focal cortical dysplasias. This could suggest that a somatic mutation
      in DEPDC5 could be responsible for the cortical dysplasia. The study aims to identify
      various genetic mutations responsible for drug-resistant focal epilepsies due to Focal
      cortical dysplasia in children undergoing surgery for epilepsies due to focal cortical
      dysplasias in Rothschild Foundation, Paris. Patients and their parents will be recruited to
      identify genetic abnormalities both in lymphocytic and cortical DNA.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>qualitative genetic analysis</measure>
    <time_frame>baseline</time_frame>
    <description>presence of genetic abnormalities, either in lymphocytic or in cortical DNA.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Cortical Dysplasia-Focal Epilepsy Syndrome</condition>
  <arm_group>
    <arm_group_label>Patients with Focal Cortical Dysplasia</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>search for genetic abnormalities</intervention_name>
    <arm_group_label>Patients with Focal Cortical Dysplasia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        children with focal drug-resistant epilepsy, undergoing epilepsy surgery, and their
        parents.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  children with focal drug-resistant epilepsy

          -  aged 6 month to 17 years old

          -  parents of these children

        Exclusion Criteria:

          -  refusal to participate in the study

          -  contraindication to anaesthesia, to MRI or to surgery

          -  no medical insurance coverage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laurence Salomon, MD</last_name>
    <phone>+33 1 48 03 64 31</phone>
    <email>lsalomon@fo-rothschild.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondation Ophtalmologique Adolphe de Rothschld</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence Salomon, MD</last_name>
      <phone>+33 1 48 03 64 31</phone>
      <email>lsalomon@fo-rothschild.fr</email>
    </contact>
    <investigator>
      <last_name>Georg Dorfm√ºller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 31, 2016</lastchanged_date>
  <firstreceived_date>August 29, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Drug Resistant Epilepsy</mesh_term>
    <mesh_term>Epilepsies, Partial</mesh_term>
    <mesh_term>Malformations of Cortical Development</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
